Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.

Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

How Praxis Packaging delivers flexible, reliable solutions for pharmaceutical contract packaging needs. As pressures on ...

With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.

Lululemon is making moves in the sustainability space by partnering with a company to expand its use of bio-based nylon. As ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...